Disparities of age-based cancer-specific survival improvement with various clinicopathologic characteristics for kidney cancer
Authors Liu K, Wang P, Zhu X, Bei Y, Zheng Z, Yan S
Received 24 March 2018
Accepted for publication 11 June 2018
Published 27 July 2018 Volume 2018:10 Pages 2259—2268
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Kenan Onel
Kaitai Liu,1,2 Ping Wang,3 Xinli Zhu,1 Yanping Bei,2 Zhen Zheng,2 Senxiang Yan1
1Department of Radiation Oncology, the First Affiliated Hospital, Zhejiang University of Medicine, Hangzhou, China; 2Department of Radiation Oncology, Lihuili Hospital, Ningbo Medical Center, Ningbo, China; 3Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, China
Introduction: Whether or not age is a predictor of kidney cancer survival is currently unknown but debated. It is also unknown whether improved kidney cancer survival is associated with age with particular clinicopathologic characteristics. The aim of this study was to evaluate kidney cancer survival in four age-based subgroups of patients by analyzing the Surveillance, Epidemiology, and End Results-registered database.
Methods: Age-based survival disparity by sex, race, marital status, year of diagnosis, pathological grade, histological type, and stage was measured. The impact of age and further parameters on disease specific mortality was evaluated by multivariate Cox proportional hazards regression analyses.
Results: Results showed that 8-year cancer-specific survival was 79.6% in those aged ≤49 years, 70.6% in those aged 50–64 years, 65.3% in those aged 65–74 years, and 56.0% in those aged 75–84 years. These differences were significant as judged by a univariate log-rank test (P<0.001) and multivariate Cox regression (P<0.001). Age-based survival improvement was most obvious in patients diagnosed from 2005 to 2009 and with the following clinicopathologic characteristics: female, white race, low pathological grade, and localized stage. There was no obvious disparity of age-based survival improvement with regard to marital status or histologic type. No age-based survival improvement was observed in patients of the black race, pathological grade IV, or distant stage (P=0.05, P=0.07, and P=0.07, respectively).
Conclusion: These data suggest that age is an independent prognostic factor for survival in patients with kidney cancer and that age-based survival improvement is associated with particular clinicopathologic characteristics.
Keywords: renal tumor, age groups, prognosis, epidemiology, SEER
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]